Benefit and danger from immunotherapy in myasthenia gravis

Amelia Evoli; Valentina Damato; Carmelo Rodolico; Giulia Nicocia; Giovanni Antonini; Rocco Liguori

doi:10.1007/s10072-021-05077-6

Benefit and danger from immunotherapy in myasthenia gravis

Amelia Evoli, Valentina Damato, Carmelo Rodolico, Giulia Nicocia, Giovanni Antonini, Rocco Liguori

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.

Lingua originale	English
pagine (da-a)	1367-1375
Numero di pagine	9
Rivista	Neurological Sciences
Volume	42
DOI	https://doi.org/10.1007/s10072-021-05077-6
Stato di pubblicazione	Pubblicato - 2021

Keywords

Checkpoint inhibitors
Refractory myasthenia gravis
Immunotherapy
Emerging therapy

Accesso al documento

10.1007/s10072-021-05077-6

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint Entra nei temi di ricerca di 'Benefit and danger from immunotherapy in myasthenia gravis'. Insieme formano una fingerprint unica.

Cita questo

@article{9856500c16454746b5bb4027a346e400,

title = "Benefit and danger from immunotherapy in myasthenia gravis",

abstract = "In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.",

keywords = "Checkpoint inhibitors, Refractory myasthenia gravis, Immunotherapy, Emerging therapy, Checkpoint inhibitors, Refractory myasthenia gravis, Immunotherapy, Emerging therapy",

author = "Amelia Evoli and Valentina Damato and Carmelo Rodolico and Giulia Nicocia and Giovanni Antonini and Rocco Liguori",

year = "2021",

doi = "10.1007/s10072-021-05077-6",

language = "English",

volume = "42",

pages = "1367--1375",

journal = "Neurological Sciences",

issn = "1590-1874",

publisher = "Springer-Verlag Italia Srl:via Decembrio 28, 20137 Milan Italy:011 39 2 5425971, EMAIL: riccardi@springer.it, Fax: 011 39 2 55193360",

}

TY - JOUR

T1 - Benefit and danger from immunotherapy in myasthenia gravis

AU - Evoli, Amelia

AU - Damato, Valentina

AU - Rodolico, Carmelo

AU - Nicocia, Giulia

AU - Antonini, Giovanni

AU - Liguori, Rocco

PY - 2021

Y1 - 2021

N2 - In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.

AB - In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.

KW - Checkpoint inhibitors

KW - Refractory myasthenia gravis

KW - Immunotherapy

KW - Emerging therapy

KW - Checkpoint inhibitors

KW - Refractory myasthenia gravis

KW - Immunotherapy

KW - Emerging therapy

UR - http://hdl.handle.net/10807/176470

U2 - 10.1007/s10072-021-05077-6

DO - 10.1007/s10072-021-05077-6

M3 - Article

VL - 42

SP - 1367

EP - 1375

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -